Marques-Piubelli, Mario L. http://orcid.org/0000-0002-6324-2096
Solis, Luisa M.
Parra, Edwin R.
Castillo, Luis Malpica
Gouni, Sushanth
Nair, Ranjit
Chihara, Dai http://orcid.org/0000-0002-1153-2294
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Wistuba, Ignacio I.
Iyer, Swaminathan P.
Vega, Francisco http://orcid.org/0000-0001-5956-452X
Strati, Paolo http://orcid.org/0000-0002-7445-1459
Article History
Received: 8 July 2021
Revised: 1 September 2021
Accepted: 3 September 2021
First Online: 16 September 2021
Competing interests
: PS is a consultant for Genentech-Roche and has received research support from AstraZeneca. FV received research funding/support from National Cancer Institute, CRISP Therapeutics, Geron Therapeutics, and honoraria from 13Health, Elsevier, America Registry of Pathology, Congressionally Directed Medical Research Program, and Society of Hematology Oncology. The remaining authors declare no competing interests.
: This study was approved by the MD Anderson Cancer Center Institutional Review Board.